Written by Cumulus | 31 December, 2021
10 December, 2021
Driving digital transformation across the UK healthcare sector
Read more
12 November, 2021
Cumulus’ CSO appears at FT Pharma conference to discuss new dementia treatments
Read more
14 September, 2021
Cumulus Neuroscience Appoints Dr Ruth McKernan CBE as Chair
Read more
25 June, 2021
Frontiers in Psychiatry paper explores feasibility of at-home EEG assessment
Read more
17 June, 2021
Cumulus Neuroscience Appoints Dr Ian Campbell to Board of Directors
Read more
4 May, 2021
Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund
Read more
5 April, 2021
Cumulus Neuroscience receives £1.8m Biomedical Catalyst grant to expand CNS biomarker platform
Read more
1 March, 2021
Cumulus Neuroscience adds Winterlight Labs’ speech analytics technology to its integrated physiological and digital biomarker platform for CNS disorders
Read more
5 January, 2021
Cumulus Neuroscience licences P1vital Product’s facial expression recognition software for use in CNS trials
Read more